Abstract

Human induced pluripotent stem cells (hiPSCs) have potential applications in cell replacement therapy and regenerative medicine. However, limited information is available regarding the immunologic features of iPSCs. In this study, expression of MHC and T cell co-stimulatory molecules in hiPSCs, and the effects on activation, proliferation and cytokine production in allogeneic human peripheral blood mononuclear cells were examined. We found that no-integrate hiPSCs had no MHC-II and T cell co-stimulatory molecules expressions but had moderate level of MHC-I and HLA-G expressions. In contrast to human skin fibroblasts (HSFs) which significantly induced allogeneic T cell activation and proliferation, hiPSCs failed to induce allogeneic CD45+ lymphocyte and CD8+ T cell activation and proliferation but could induce a low level of allogeneic CD4+ T cell proliferation. Unlike HSFs which induced allogeneic lymphocytes to produce high levels of IFN-γ, TNF-α and IL-17, hiPSCs only induced allogeneic lymphocytes to produce IL-2 and IL-10, and promote IL-10-secreting regulatory T cell (Treg) generation. Our study suggests that the integration-free hiPSCs had low or negligible immunogenicity, which may result from their induction of IL-10-secreting Treg.

Highlights

  • Development of innovative strategies to prevent allograft rejection is a focus of transplantation medicine

  • To demonstrate the quality and undifferentiated phenotype of Human induced pluripotent stem cells (hiPSCs) used in this study, the expressions of octamer-binding nuclear transcriptional factor 4 (OCT4), SSEA-4, TRA-1-60, and TRA-1-81 in hiPSCs were analyzed by flow cytometry; more than 95% of hiPSCs were positive for these markers (Fig. 1A)

  • In addition to classical MHC proteins, we further analyzed the expression of non-classical MHC-I antigens (HLA-E and HLA-G) in hiPSCs. hiPSCs expressed moderate level of HLA-E, the level is lower than that in human skin fibroblasts (HSFs). hiPSCs expressed low level of HLA-G, whereas there was no HLA-G expression in HSFs (Fig. 2)

Read more

Summary

Introduction

Development of innovative strategies to prevent allograft rejection is a focus of transplantation medicine. In addition to solid organ transplantation, cellular transplantation involved in tissue restoration should take into account the potential for rejection and need to induce immune tolerance [1]. The successful isolation of human embryonic stem cells (hESCs) provided a valuable source for cell replacement therapy [2]. Various studies have confirmed that hESCs have powerful therapeutic potential [3,4,5,6]. HESC-based therapy is associated with ethical challenges. The recent groundbreaking invention of induced pluripotent stem cells (iPSCs) contribute to an alternative candidate for regenerative medicine

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call